摘要
目的探讨盐酸氮卓斯汀鼻喷雾剂联合糠酸莫米松鼻喷雾剂、氯雷他定片治疗变应性鼻炎对患者临床疗效和炎性因子水平的影响。方法选取2019年6月-2020年4月就诊于东莞市清溪医院的80例患者,按随机数字表法分为两组,各40例。对照组予以糠酸莫米松鼻喷雾剂、氯雷他定片治疗,观察组加用盐酸氮卓斯汀鼻喷雾剂治疗。比较两组临床疗效、炎性因子水平和不良反应发生情况。结果观察组治疗总有效率为95.00%,高于对照组的80.00%,有统计学差异(P<0.05);治疗后,观察组白介素-4(IL-4)、白介素-6(IL-6)为(13.25±1.68)ng/L、(95.36±8.72)ng/L,低于对照组的(16.08±1.73)ng/L、(109.41±8.95)ng/L,白介素-10(IL-10)为(17.65±2.52)ng/L,高于对照组的(13.57±2.06)ng/L,有统计学差异(P<0.05);两组均无严重不良反应发生。结论联用盐酸氮卓斯汀鼻喷雾剂、糠酸莫米松鼻喷雾剂和氯雷他定片可增强变应性鼻炎治疗效果,促进局部炎症消失,稳定控制临床症状,安全可靠。
Objective To investigate the effects of azelastine hydrochloride nasal spray,momethasone furoate nasal spray and loratadine tablets on the clinical efficacy and the level of inflammatory factors in patients with allergic rhinitis.Methods 80 patients admitted to our hospital from June 2019 to April 2020 were selected and divided into two groups according to random number table method,with 40 patients in each group.The control group was treated with momethasone furoate nasal spray and loratadine tablets,and the observation group was treated with azelastine hydrochloride nasal spray.Clinical efficacy,inflammatory factors and adverse reactions were compared between the two groups.Results The total effective rate of the observation group was 95.00%,which was higher than that of the control group(80.00%),with statistical difference(P<0.05).After treatment,the levels of interleukin-4(IL-4)and interleukin-6(IL-6)in the observation group were(13.25±1.68)ng/L and(95.36±8.72)ng/L,which were lower than those in the control group(16.08±1.73)ng/L and(109.41±8.95)ng/L.Interleukin-10(IL-10)was(17.65±2.52)ng/L,higher than the control group(13.57±2.06)ng/L,the difference was statistically significant(P<0.05).There was no serious adverse reaction in both groups.Conclusion The combination of azolastine hydrochloride nasal spray,mometasone furoate nasal spray and loratadine tablets can enhance the therapeutic effect of allergic rhinitis,promote the disappearance of local inflammation,stabilize and control clinical symptoms,and is safe and reliable.
作者
何醒文
梁亚凤
HE Xing-wen;LIANG Ya-feng(Dongguan Qingxi hospital,Dongguan,Guangdong 523660)
出处
《智慧健康》
2021年第32期103-105,共3页
Smart Healthcare
